fly wellness tirzepatide Injections: How It Helps Treat Obesity the dual With tirzepatide you can lose

Muscle loss slows your metabolism, weakens your bones, and can make weight regain more likely if you ever discontinue the medication

Limited coverage possible for CV risk reduction indication

A registered dietitian can personalize your nutrition plan to support hair health while on tirzepatide

Home Medical news & Guidelines Anesthesiology Cardiology and CTVS Critical Care Dentistry Dermatology Diabetes and Endocrinology ENT Gastroenterology Medicine Nephrology Neurology Obstretics-Gynaecology Oncology Ophthalmology Orthopaedics Pediatrics-Neonatology Psychiatry Pulmonology Radiology Surgery Urology Laboratory Medicine Diet Nursing Paramedical Physiotherapy Health news Fact Check Bone Health Fact Check Brain Health Fact Check Cancer Related Fact Check Child Care Fact Check Dental and oral health fact check Diabetes and metabolic health fact check Diet and Nutrition Fact Check Eye and ENT Care Fact Check Fitness fact check Gut health fact check Heart health fact check Kidney health fact check Medical education fact check Men's health fact check Respiratory fact check Skin and hair care fact check Vaccine and Immunization fact check Women's health fact check AYUSH State News Andaman and Nicobar Islands Andhra Pradesh Arunachal Pradesh Assam Bihar Chandigarh Chattisgarh Dadra and Nagar Haveli Daman and Diu Delhi Goa Gujarat Haryana Himachal Pradesh Jammu & Kashmir Jharkhand Karnataka Kerala Ladakh Lakshadweep Madhya Pradesh Maharashtra Manipur Meghalaya Mizoram Nagaland Odisha Puducherry Punjab Rajasthan Sikkim Tamil Nadu Telangana Tripura Uttar Pradesh Uttrakhand West Bengal Medical Education Industry Tirzepatide significantly reduces predicted risk of ASCVD among patients with obesity without diabetes The results of the phase 3 trial reveal that tirzepatide treatment over 72 weeks significantly reduced the 10-year predicted risk of ASCVD versus placebo in patients with obesity or overweight without diabetes

This weight loss continued for another two weeks after cessation of treatment, peaking at a mean weight reduction of 13.5% from baseline

Neetu Nebhwani in Danville and San Jose